Eli Lilly-backed TRex Bio is aiming for a $111.3 million IPO, while hypertension-focused Retension Pharmaceuticals hopes for ...
Genentech is paying Alector $100 million upfront for exclusive rights to a preclinical drug candidate that targets a driver ...
Vaxcyte has seen its stock jump after the biotech’s 31-valent pneumococcal vaccine candidate went head-to-head with Pfizer’s Prevnar 20 and Merck & Co.’s Capvaxive in a phase 3 contest. The biotech ...
Eli Lilly has been pushing at an open door by tacking on $870 million in biobucks to its existing collaboration with Gate Bioscience. | Eli Lilly has been pushing at an open door by tacking on $870 ...
The FDA has approved a surgically implanted pulmonary heart valve for pediatric patients with congenital pulmonary valve disease. | The FDA has approved a surgically implanted pulmonary heart valve ...
Click Therapeutics has nabbed FDA approval for its digital therapeutic Motivista, which now becomes the first authorized ...
Genmab has linked an antibody-drug conjugate (ADC) to median progression-free survival (PFS) of 9.5 months, leading TD Cowen ...
Sanofi is paying Regeneron $1 billion upfront to collaborate on four early-stage im | Sanofi is paying Regeneron $1 billion ...
As Foghorn digested the end of the Lilly partnership, the biotech said it was laying off 40% of its workforce, while “further ...
Merck touted a win for its anti-TL1A antibody in a phase 2b trial in patients with moderate to severe hidradenitis ...
The Danish drugmaker is paying $300 million upfront to China’s Hengrui Pharma for a preclinical GLP-1/GIP dual receptor ...
Base editing biotech Beam Therapeutics is suing one of its newest rivals, alleging that the upstart company stole the secrets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results